RT Journal Article
SR Electronic
T1 Predicting bipolar disorder incidence in young adults using gradient boosting: a 5-year follow-up study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.31.22282507
DO 10.1101/2023.03.31.22282507
A1 Montezano, Bruno Braga
A1 Gnielka, Vanessa
A1 Shintani, Augusto Ossamu
A1 de Aguiar, Kyara Rodrigues
A1 Roza, Thiago Henrique
A1 de Azevedo Cardoso, Taiane
A1 de Mattos Souza, Luciano Dias
A1 Moreira, Fernanda Pedrotti
A1 da Silva, Ricardo Azevedo
A1 Mondin, Thaíse Campos
A1 Jansen, Karen
A1 Passos, Ives Cavalcante
YR 2023
UL http://medrxiv.org/content/early/2023/04/03/2023.03.31.22282507.abstract
AB This study aimed to develop a classification model predicting incident bipolar disorder (BD) cases in young adults within a 5-year interval, using sociodemographic and clinical features from a large cohort study. We analyzed 1,091 individuals without BD, aged 18 to 24 years at baseline, and used the XGBoost algorithm with feature selection and oversampling methods. Forty-nine individuals (4.49%) received a BD diagnosis five years later. The best model had an acceptable performance (test AUC: 0.786, 95% CI: 0.686, 0.887) and included ten features: feeling of worthlessness, sadness, current depressive episode, selfreported stress, self-confidence, lifetime cocaine use, socioeconomic status, sex frequency, romantic relationship, and tachylalia. We performed a permutation test with 10,000 permutations that showed the AUC from the built model is significantly better than random classifiers. The results provide insights into BD as a latent phenomenon, as depression is its typical initial manifestation. Future studies could monitor subjects during other developmental stages and investigate risk populations to improve BD characterization. Furthermore, the usage of digital health data, biological, and neuropsychological information and also neuroimaging can help in the rise of new predictive models.Competing Interest StatementIves Cavalcante Passos receives authorship royalties from Springer Nature and ArtMed. Ives Cavalcante Passos has served as consultant, advisor, or CME speaker for the following entities: Janssen, LundBeck, Libbs, Daiichi Sankyo, EMS and Pfizer. The other authors have no conflicts of interest to disclose.Funding StatementThis study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001. This work received financial supports from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) [grant numbers 481998/2012-8-APQ]; FAPERGS (Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul) [grant numbers 19/2551- 0000689-6]; and Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM) [grant numbers 2014/50891-1/FAPESP; 465458/2014-9/CNPQ], to conduct the study design and data collection. Ives Cavalcante Passos is a CNPq research fellow. This work received financial supports from Fundo de Incentivo à Pesquisa e Eventos (FIPE) do HCPA, Brazil.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Research Ethics Committee of Universidade Católica de Pelotas (UCPel) under protocol number 2008/118.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResearch data are not shared due to privacy and anonymity reasons outlined by the authors of the original research project.